Home |
Climate Change Project |
Table of Contents |
Courses | Search |
![]()
From the U.S. House of Representatives Downloadable U.S. Code
[uscode.house.gov]
[Laws in effect as of January 5, 1999]
[CITE: 42USC300cc-12]
TITLE 42 - THE PUBLIC HEALTH AND WELFARE
CHAPTER 6A - PUBLIC HEALTH SERVICE
SUBCHAPTER XXI - RESEARCH WITH RESPECT TO ACQUIRED IMMUNE
DEFICIENCY SYNDROME
Part B - Research Authority
-HEAD-
Sec. 300cc-12. Use of investigational new drugs with respect to
acquired immune deficiency syndrome
-STATUTE-
(a) Encouragement of applications with respect to clinical trials
(1) If, in the determination of the Secretary, there is
preliminary evidence that a new drug has effectiveness in humans
with respect to the prevention or treatment of acquired immune
deficiency syndrome, the Secretary shall, through statements
published in the Federal Register -
(A) announce the fact of such determination; and
(B) with respect to the new drug involved, encourage an
application for an exemption for investigational use of the new
drug under regulations issued under section 355(i) of title 21.
(2)(A) The AIDS Research Advisory Committee established pursuant
to section 300cc-3 of this title shall make recommendations to the
Secretary with respect to new drugs appropriate for determinations
described in paragraph (1).
(B) The Secretary shall, as soon as is practicable, determine the
merits of recommendations received by the Secretary pursuant to
subparagraph (A).
(b) Encouragement of applications with respect to treatment use in
circumstances other than clinical trials
(1) In the case of a new drug with respect to which the Secretary
has made a determination described in subsection (a) of this
section and with respect to which an exemption is in effect for
purposes of section 355(i) of title 21, the Secretary shall -
(A) as appropriate, encourage the sponsor of the investigation
of the new drug to submit to the Secretary, in accordance with
regulations issued under such section, an application to use the
drug in the treatment of individuals -
(i) who are infected with the etiologic agent for acquired
immune deficiency syndrome; and
(ii) who are not participating in the clinical trials
conducted pursuant to such exemption; and
(B) if such an application is approved, encourage, as
appropriate, licensed medical practitioners to obtain, in
accordance with such regulations, the new drug from such sponsor
for the purpose of treating such individuals.
(2) If the sponsor of the investigation of a new drug described
in paragraph (1) does not submit to the Secretary an application
described in such paragraph (relating to treatment use), the
Secretary shall, through statements published in the Federal
Register, encourage, as appropriate, licensed medical practitioners
to submit to the Secretary such applications in accordance with
regulations described in such paragraph.
(c) Technical assistance with respect to treatment use
In the case of a new drug with respect to which the Secretary has
made a determination described in subsection (a) of this section,
the Secretary may, directly or through grants or contracts, provide
technical assistance with respect to the process of -
(1) submitting to the Secretary applications for exemptions
described in paragraph (1)(B) of such subsection;
(2) submitting to the Secretary applications described in
subsection (b) of this section; and
(3) with respect to sponsors of investigations of new drugs,
facilitating the transfer of new drugs from such sponsors to
licensed medical practitioners.
(d) ''New drug'' defined
For purposes of this section, the term ''new drug'' has the
meaning given such term in section 321 of title 21.
-SOURCE-
(July 1, 1944, ch. 373, title XXIII, Sec. 2312, as added Pub. L.
100-607, title II, Sec. 201(4), Nov. 4, 1988, 102 Stat. 3066;
amended Pub. L. 103-43, title XX, Sec. 2008(d)(2), June 10, 1993,
107 Stat. 212.)
-MISC1-
PRIOR PROVISIONS
A prior section 300cc-12, act July 1, 1944, Sec. 2313, was
successively renumbered by subsequent acts and transferred, see
section 238j of this title.
AMENDMENTS
1993 - Subsec. (a)(2)(A). Pub. L. 103-43 substituted ''AIDS
Research Advisory Committee'' for ''AIDS Clinical Research Review
Committee''.
FDA/Website Management Staff
Web page created by smc 2000-NOV-14.
The Climate Change and Public Health Law Site
The Best on the WWW Since 1995!
Copyright as to non-public domain materials
See DR-KATE.COM for home hurricane and disaster preparation
See WWW.EPR-ART.COM for photography of southern Louisiana and Hurricane Katrina
Professor Edward P. Richards, III, JD, MPH - Webmaster
Provide Website Feedback - https://www.lsu.edu/feedback
Privacy Statement - https://www.lsu.edu/privacy
Accessibility Statement - https://www.lsu.edu/accessibility